Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Antoine Jean
Antoine Jean Bruguier, Milpitas, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100128969 | HARMONIC RESIST MODEL FOR USE IN A LITHOGRAPHIC APPARATUS AND A DEVICE MANUFACTURING METHOD - A method for determining an image of a mask pattern in a resist coated on a substrate, the method including determining an aerial image of the mask pattern at substrate level; and convolving the aerial image with at least two orthogonal convolution kernels to determine a resist image that is representative of the mask pattern in the resist. | 05-27-2010 |
Antoine Jean Girbal, Los Gatos, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20110276623 | FILE BUNDLING FOR CACHE SERVERS OF CONTENT DELIVERY NETWORKS - Data access time in content delivery networks is improved by storing files in cache servers as file bundles. A cache server determines that multiple files are requested by the same client based on information available in the request including the IP address of the client, a URL of a webpage referring to the file, and/or a cookie stored at a client. The cache server stores multiple files requested by the same client on the hard drive as a file bundle with meta data associating the files with one another, such that they can be accessed together. A future request from the client for a file in a file bundle results in multiple files from the file bundle being loaded in the memory. If the client requests another file from the file bundle, the file is accessed directly from the memory instead of the hard drive, resulting in improved performance. | 11-10-2011 |
Antoine Jean Yver, Belle Mead, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20120035347 | INTERFERON-ALFA SENSITIVITY BIOMARKERS - The present invention provides biomarkers of sensitivity to interferon alfa (IFN-α). These IFN-α sensitivity biomarkers are useful, inter alia, to identify patients who are most likely to benefit from treatment with pharmaceutical compositions of IFN-α, in methods of treating patients having a disease susceptible to treatment with interferon alfa, and in methods for selecting the most appropriate therapy for such patients. | 02-09-2012 |